OpSens Reports Annual General and Special Shareholders Meeting Voting Results

QUEBEC CITY, Jan. 25, 2023 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Corporation") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, announces the voting results following its annual general and special meeting of shareholders held virtually at 10:00 a.m. on Tuesday, January 24, 2023 (the "Meeting").

1.  Election of Directors

Based on the proxies received and the votes cast at the Meeting, the following individuals were elected as directors of the Corporation until the next annual shareholders' meeting. Accordingly, the voting results are set out below:

Name	Votes For	Percentage of Votes For (%)	Percentage of Votes Withheld	Percentage of Votes Withheld (%)
Lori Chmura	40,748,192	90.82	4,116,887	9.18
Gaétan Duplain	44,722,648	99.68	142,431	0.32
Denis M. Sirois	27,567,754	61.45	17,297,325	38.55
Denis Harrington	40,588,181	90.47	4,276,898	9.53
Jean Lavigueur	44,719,670	99.68	145,409	0.32
Louis Laflamme	44,358,789	98.87	506,290	1.13
James Patrick Mackin	40,443,440	90.14	4,421,639	9.86
Alan Milinazzo	44,709,092	99.65	155,987	0.35

2. Appointment of Deloitte LLP as Independent Auditor of the Corporation and Authorization Given to Directors to Set Its Compensation

Based on the proxies received and the votes cast at the Meeting, Deloitte LLP was appointed as independent auditor of the Corporation for the ensuing year and the directors were authorized to fix its compensation, with the following voting results:

Independent  Auditor	Votes For	Percentage of Votes For (%)	Percentage of Votes Withheld	Percentage of Votes Withheld (%)
Deloitte LLP	54,367,086	96.22	2,136,023	3.78

The report of the voting results is also available on SEDAR at www.sedar.com.

About OpSens Inc. (www.OpSens.com or www.OpSensmedical.com)

OpSens focuses mainly on cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of more than 200,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

OpSens has recently received FDA clearance and Health Canada approval to commercialize the SavvyWire for transcatheter aortic valve replacement procedures (TAVR).

The TAVR procedure is growing rapidly globally, driven by the aging population and recent studies that demonstrate its benefits for a broader array of patients. The global TAVR market is currently estimated at over 200,000 procedures and is expected to reach 400,000 in 2027.

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

SOURCE OpSens Inc.

Louis Laflamme, CPA, President, Chief Executive Officer and Interim Chief Financial Officer, 418.781.0333